- Home
- LDWY vs APM Comparison
LDWY vs APM Comparison
Compare LDWY & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- APM
- Stock Information
- Founded
- LDWY 1990
- APM 2010
- Country
- LDWY United States
- APM United Kingdom
- Employees
- LDWY N/A
- APM N/A
- Industry
- LDWY Advertising
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- APM Health Care
- Exchange
- LDWY Nasdaq
- APM Nasdaq
- Market Cap
- LDWY 6.9M
- APM 8.3M
- IPO Year
- LDWY 1991
- APM 2018
- Fundamental
- Price
- LDWY $4.12
- APM $1.10
- Analyst Decision
- LDWY
- APM
- Analyst Count
- LDWY 0
- APM 0
- Target Price
- LDWY N/A
- APM N/A
- AVG Volume (30 Days)
- LDWY 5.3K
- APM 175.0K
- Earning Date
- LDWY 03-31-2025
- APM 12-20-2024
- Dividend Yield
- LDWY N/A
- APM N/A
- EPS Growth
- LDWY N/A
- APM N/A
- EPS
- LDWY N/A
- APM 0.00
- Revenue
- LDWY $31,581,000.00
- APM N/A
- Revenue This Year
- LDWY N/A
- APM $157,729.10
- Revenue Next Year
- LDWY N/A
- APM N/A
- P/E Ratio
- LDWY N/A
- APM $424.93
- Revenue Growth
- LDWY N/A
- APM N/A
- 52 Week Low
- LDWY $3.02
- APM $0.46
- 52 Week High
- LDWY $6.88
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- LDWY 45.61
- APM 45.00
- Support Level
- LDWY $3.85
- APM $1.02
- Resistance Level
- LDWY $4.75
- APM $1.80
- Average True Range (ATR)
- LDWY 0.17
- APM 0.14
- MACD
- LDWY -0.01
- APM -0.02
- Stochastic Oscillator
- LDWY 30.00
- APM 9.63
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.